BILLERICA, Mass.--(BUSINESS WIRE)--RainDance Technologies, Inc., the Digital Biology™ Company, announced a publication demonstrating the use of the company’s digital PCR technology for detecting mutations in circulating tumor DNA directly from blood samples. The paper, co-authored by a consortium of research clinicians in France and RainDance scientists, highlights the significant value unlocked by the company’s digital PCR platform for non-invasive monitoring of multiple cancer mutations obtained from a simple blood draw, as an alternative to invasive tissue biopsy.